Where Are We With Treatment and Prevention of Heart Failure in Patients Post-Myocardial Infarction
Source : https://pubmed.ncbi.nlm.nih.gov/38878010/
As a result of the widespread use of reperfusion therapies and secondary prevention over the last 30 years, there has been a dramatic reduction in the risk of mortality and...
Despite advances in reperfusion and secondary prevention, chronic heart failure (HF) remains common post-myocardial infarction (MI). Neurohormonal inhibition and emerging therapies aim to mitigate HF risk and myocardial damage.
The current best drug treatment for hypertensive heart failure with preserved ejection fraction
Source : https://pubmed.ncbi.nlm.nih.gov/37865559/
More than 90 % of patients developing heart failure (HF) have hypertension. The most frequent concomitant conditions are type-2 diabetes mellitus, obesity, atrial fibrillation, and coronary disease. HF outcome research...
Heart failure (HF) treatment involves antihypertensives and other drugs, regardless of left ventricular ejection fraction (LVEF). Focus on symptom management, signs, severity, and comorbid conditions.
Heart Transplantation
Source : https://pubmed.ncbi.nlm.nih.gov/38256691/
Heart transplantation (HTx) remains the last therapeutic resort for patients with advanced heart failure. The present work is a clinically focused review discussing current issues in heart transplantation. Several factors...
Heart transplantation advances include xenotransplantation, hepatitis C donors, improved rejection monitoring, and novel immunosuppressants, enhancing outcomes for patients with advanced heart failure.
Exercise intolerance in heart failure with preserved ejection fraction: Causes, consequences and the journey towards a cure
Source : https://pubmed.ncbi.nlm.nih.gov/38063130/
Heart failure with preserved ejection fraction (HFpEF) accounts for over 50% of all heart failure cases nationwide and continues to rise in its prevalence. The complex, multi-organ involvement of the...
HFpEF's complex pathophysiology involves both cardiac and non-cardiac factors. Improving vascular health through interventions could enhance outcomes, underscoring the need for an integrative approach to treatment.
Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions-Part II: Combination Therapy
Source : https://pubmed.ncbi.nlm.nih.gov/38300391/
We will assess recent trials, including DOSE, TRANSFORM, ADVOR, CLOROTIC, OSPREY-AHF, and PUSH-AHF, and assess how these may influence current practice and future research. There are few data on which...
Fluid retention in heart failure (HF) is managed primarily with loop diuretics, needing updated research to optimize treatment strategies and improve guidelines.